PUBLISHER: Orion Market Research | PRODUCT CODE: 1433394
PUBLISHER: Orion Market Research | PRODUCT CODE: 1433394
Global Skin Biopsy Market Size, Share &Trends Analysis Report by Type (Shave Biopsy, Punch Biopsy, and Excisional Biopsy), by Indication (Skin Cancer Diagnosis and Staging, Actinic keratosis, Dermatitis, and Others) and by End-User (Hospitals, Diagnostic Laboratories, and Others), Forecast Period (2023-2030)
The global skin biopsy market is anticipated to grow at a considerable CAGR of 6.8% during the forecast period (2023-2030).The market's growth is attributed to the demand for advanced skincare products. Consumer demand for high-quality skincare products, particularly those designed with prominent and scientifically validated components such as HA, peptides, and antioxidants, continues to rise. The launch of new products stimulates interest and investigation in the skincare sector. For instance, in December 2022, Hydrinity Accelerated Skin Science launched new facial skin care line with well-known ingredients of hyaluronic acid (HA), PPM technology, and numerous peptides and antioxidants. The new skin care line includes a renewing HA serum, a hydrating and healing serum, and a lightweight, microbiome-friendly purifying mist, all designed to reduce signs of aging, improve texture, and accelerate skin healing. However, the high cost of skin biopsy may restrain its growth in low-income economies.
The global skin biopsy market is segmented on the type, indication, and end-user. Based on the type, the market is sub-segmented into shave biopsy, punch biopsy, and excisional biopsy. Based on the indication, the market is sub-segmented into skin cancer diagnosis and staging, actinic keratosis, dermatitis, and others. Furthermore, on the basis of end-user, the market is sub-segmented into hospitals, diagnostic laboratories, and others. The skin cancer diagnosis and staging subcategory is expected to capture a significant portion of the market share within the indication segment. The growth can be attributed to the skin cancer prevalence is increasing, and skin diseases have been diagnosed earlier. In addition, skin cancer needs to be detected and treated as soon as possible to avoid the need for surgery in the case of a dangerous melanoma or other skin cancer.
Among the end-user, the diagnostic laboratories sub-segment is expected to hold a considerable share in the global Skin Biopsy market. The segmental growth is attributed to the innovative diagnostic approaches. The use of skin biopsy samples to diagnose Alzheimer's disease is an innovative method in neurology. Such innovative approaches broaden the applications of skin biopsies outside dermatology, helping to diversify the skin biopsy industry. For instance, in February 2023, SynapsDx Prepares Launched Skin-Based Alzheimer's Disease Diagnostic Test. Synaps uses three biomarkers to diagnose Alzheimer's disease and differentiate it from other dementia forms. The primary diagnosis is based on morphometric imaging, that measures cell growth in fibroblasts from a patient's skin sample. Alzheimer's patients have fewer large aggregates.
The global skin biopsy market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to increased awareness of skin health, diagnosis, and treatment processes is expected to drive the market throughout the forecast period.
The North America Holds Considering the global Skin Biopsy Market
Regional growth is attributed to the medical need for pediatric skin biopsies. The observations highlight the importance of skin biopsies in the diagnosis of pediatric skin disorders. As a result children and adolescents account for a sizable proportion of biopsy cases, the demand for biopsy equipment and services tailored to younger patients has the potential to drive market expansion.
According to the National Institute of Government, in June 2023, a study analyzed 1308 biopsy records, revealing a male predominance and a majority of patients were adolescents. Furthermore, study found that 12.9% of pediatric skin biopsies were performed, with 83.9% of patients underwent a single biopsy. The majority of patients underwent multiple biopsies, with 98% performing a biopsy for diagnostic purposes. The mean age of patients was 12 years, with males outnumbering females. The study emphasizes the importance of skin biopsies in pediatric patients and the high clinic-histopathologic agreement. Leprosy and papulosquamous diseases were the most common cases.
The major companies serving the skin biopsy market includes Cardinal Health Inc., AccTec Inc., Beckton, Dickenson, and Company, Bio-Rad Laboratories Inc., and Kai Group among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market.
For instance in June 2019,Proscia Launched DermAI to Pre-Screen and Classify Skin Biopsies. Proscia's AI-powered software can classify skin disease variants into pre-diagnostic categories, enhancing pathology confidence, quality, and speed, reducing errors and improving laboratory efficiency.